BioSpace News Archive

Tiziana Life Sciences Ltd. today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS).

Casterra Ag Ltd today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company’s expansion efforts.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injection (R&D code: 8MW0511) has been accepted by the National Medical Products Administration (NMPA).

HuidaGene Therapeutics (辉大基因"HuidaGene”) today announced the U.S. FDA granted Rare Pediatric Drug Designation (RPDD) to HG302, a novel CRISPR-Cas12 DNA-editing therapy, to treat Duchenne muscular dystrophy (DMD), affecting 1 in ~5,000 newborn boys.

Element Biosciences, Inc. today announced that Element CEO and Co-Founder Molly He will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

FGen AG, a subsidiary of Ginkgo Bioworks, based in Switzerland, has been awarded funding through the European Innovation Council’s Pathfinder Challenge program.

Compugen Ltd. today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to treat multiple tumor types.

Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of Part B of its Phase 1 comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in patients with atopic dermatitis.

Alora Pharmaceuticals, LLC , the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii ® (methylphenidate hydrochloride extended-release tablets).